Abbott Laboratories ABT
NYSE · United States · Health Technology
$98.83-2.12 (-2.10%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Lazada, a leading eCommerce platform in Southeast Asia, celebrated the achievements of its 170,000-strong brand ecosystem at the annual LazMall Brand Gala 2026, as more brands reached major sales milestones on the platform.
Abbott Laboratories (ABT) expanded its presence in cancer screening with the launch of SimpleScreen CRC in the US. The test is an FDA-approved blood-based option for average-risk adults who decline traditional colorectal screening methods. Against that product backdrop, Abbott Laboratories has seen its 1 month share price return fall about 10.2%, while the 90 day share price return is up 9.5%. This points to fading short term momentum compared with a still positive multi quarter trend. Recent...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.